Clinical trials: Cytokine Release Syndrome
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cytokine Storm, SARS-CoV-2
RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time…
- Trial name
- STORM (NCT04433078)
- Testing
- Doxycycline
- Where
- United States
- Sponsor
- Temple University
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Solid Tumor, Hematological Malignancy
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T)…
- Trial name
- NCT04082910
- Testing
- Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
COVID-19, ARDS
Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS
Critical ill COVID-19 patients often develop respiratory, hemodynamic and neuropsychiatric complications. An imbalance of sympatho-parasympathetic nervous system is discussed as one of the reasons.
- Conditions
- COVID-19, ARDS, Cytokine Storm
- Trial name
- NCT05058742
- Testing
- AuriStim
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Vienna Hospital Association
Cytokine Release Syndrome, Covid-19
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19
- Trial name
- NCT04377503
- Testing
- Tocilizumab 180 MG/ML, Methylprednisolone Sodium Succinate
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Sao Domingos
Cytokine Release Syndrome, Sepsis
Cytokine Removal With CVVHD Compared to CVVH
Septic patients with acute kidney injury (SA-AKI) requiring continuous renal replacement therapies (CRRT) present high mortality due to systemic inflammatory response, cytokine liberation, and finally multiorgan dysfunction.
- Conditions
- Cytokine Release Syndrome, Sepsis, AKI
- Trial name
- NCT04048525
- Testing
- CVVHD, CVVH
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Universitari de Bellvitge
Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of…
- Trial name
- EMBRACE (NCT06421675)
- Testing
- Elranatamab injection
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
COVID-19, SARS
Modulation of Hyperinflammation in COVID-19
Current treatment recommendations are based on very limited evidence and reliant on the deployment of pharmacological strategies of doubtful efficacy, high toxicity, and near universal shortages of supply.
- Trial name
- NCT04353674
- Testing
- Control group, SLEDD with a L-MOD
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory…
- Conditions
- Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity
- Trial name
- NCT04150913
- Testing
- Anakinra, Axicabtagene Ciloleucel
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or "telemedicine" visit.
- Conditions
- Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT04503538
- Testing
- Telemedicine visit
- Sponsor
- Wake Forest University Health Sciences
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy
Pre-emptive Anakinra for Cytokine Event Reduction
Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (CRS) following CD19-directed chimeric antigen receptor (CAR) T-cell…
- Conditions
- B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- PACER (NCT06703216)
- Testing
- Anakinra (Kineret®)
- Where
- United States
- Sponsor
- Kevin McNerney
Cytokine Storm, COVID-19
Early Treatment of Cytokine Storm Syndrome in Covid-19
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
- Trial name
- NCT04362111
- Testing
- Anakinra, Normal saline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Covid19, Cytokine Storm
Menstrual Blood Stem Cells in Severe Covid-19
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of menstrual blood stem cells.
- Trial name
- NCT05019287
- Testing
- Allogeneic human menstrual blood stem cells secretome, Intravenous saline injection
- Where
- Iran
- Volunteers
- 29 people
- Sponsor
- Avicenna Research Institute
Septic Shock, Cytokine Storm
Cytokine Adsorption in Severe, Refractory Septic Shock
Septic shock and the underlying dysregulated inflammatory host-response remain a major contributor to mortality in critically ill patients. Cytokine adsorption represents an attractive approach to the treatment of septic shock.
- Trial name
- NCT04910893
- Testing
- Cytokine Adsorption, Standard of Care
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Cardiac Surgery Recovery, Inflammation
Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries
This prospective single-center randomized controlled trial aims at evaluating the safety and feasibility of an hemoadsorption protocol using Jafron HA-60 during cardio-pulmonary bypass in 20 pediatric patients undergoing…
- Conditions
- Cardiac Surgery Recovery, Inflammation, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Cytokine Storm
- Trial name
- JACKPOT (NCT07393087)
- Testing
- Hemoadsorption
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Coronavirus Infection, COVID
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus Infection, COVID, SARS-CoV 2, Respiratory Failure
- Trial name
- CYCOV-II (NCT04385771)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Dr. Alexander Supady
Hemophagocytic Lymphohistiocytoses, Cytokine Storm
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children.
- Trial name
- NCT05491304
- Testing
- Dexamethasone, Etoposide, Ruxolitinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine